Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 3,520 Shares of Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 3,520 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total transaction of $143,228.80. Following the transaction, the insider now owns 252,623 shares in the company, valued at approximately $10,279,229.87. This represents a 1.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, January 2nd, Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.94, for a total value of $191,749.90.
• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The stock was sold at an average price of $48.76, for a total value of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.07, for a total value of $307,056.55.

Apogee Therapeutics Stock Performance

Shares of NASDAQ:APGE opened at $39.72 on Friday. The stock’s 50-day moving average is $44.25 and its 200-day moving average is $48.53. The company has a market cap of $1.79 billion, a P/E ratio of -16.41 and a beta of 2.18. Apogee Therapeutics, Inc. has a 52-week low of $33.14 and a 52-week high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Tuesday, November 12th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.13). As a group, equities analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Institutional Trading of Apogee Therapeutics

A number of hedge funds have recently modified their holdings of the company. Wellington Management Group LLP increased its position in shares of Apogee Therapeutics by 35.7% during the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after purchasing an additional 1,267,451 shares during the period. Waypoint Capital Advisors LLC acquired a new stake in Apogee Therapeutics during the third quarter worth $36,835,000. Janus Henderson Group PLC increased its holdings in Apogee Therapeutics by 4,018.9% in the 3rd quarter. Janus Henderson Group PLC now owns 469,557 shares of the company’s stock valued at $27,586,000 after buying an additional 458,157 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Apogee Therapeutics by 162.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock valued at $41,545,000 after buying an additional 438,036 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Apogee Therapeutics by 369.2% during the 3rd quarter. Barclays PLC now owns 365,046 shares of the company’s stock worth $21,443,000 after acquiring an additional 287,243 shares during the period. Institutional investors own 79.04% of the company’s stock.

Analyst Ratings Changes

APGE has been the topic of several recent research reports. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research report on Thursday, December 12th. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Finally, Wedbush boosted their price target on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a research report on Monday, December 2nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $89.71.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.